Abstract
Since recombinant gene technology was established to provide rare important regulatory proteins as recombinant molecules, cytokine therapies have widely developed and enormously contributed to the treatment of various diseases, nevertheless, it has been revealed that recombinant therapeutic molecules are not always perfect because of sideeffects related to pharmacological functions of cytokines and / or potential antigenicity observed in some clinical cases. Although studies on the antigenicity of recombinant proteins have initiated, and observations in clinical studies have been accumulated over this decade, mechanisms of the autoantibody production are not clarified yet. Among various hematopoietic growth factors introduced into clinical trials, this report summarizes current issues of autoantibodies to primary regulators for terminal hematopoiesis.
Keywords: anemia, autoantibody, cytokine, erythropoietin, g-csf, hematopoietic growth factor, peg-rhumgdf, thrombocytopenia, thrombopoietin
Current Pharmaceutical Design
Title: Therapeutically-induced Autoantibodies in Patients Treated with Recombinant Hematopoietic Growth Factors: A Brief Summary
Volume: 9 Issue: 14
Author(s): Takashi Kato and Hiroshi Miyazaki
Affiliation:
Keywords: anemia, autoantibody, cytokine, erythropoietin, g-csf, hematopoietic growth factor, peg-rhumgdf, thrombocytopenia, thrombopoietin
Abstract: Since recombinant gene technology was established to provide rare important regulatory proteins as recombinant molecules, cytokine therapies have widely developed and enormously contributed to the treatment of various diseases, nevertheless, it has been revealed that recombinant therapeutic molecules are not always perfect because of sideeffects related to pharmacological functions of cytokines and / or potential antigenicity observed in some clinical cases. Although studies on the antigenicity of recombinant proteins have initiated, and observations in clinical studies have been accumulated over this decade, mechanisms of the autoantibody production are not clarified yet. Among various hematopoietic growth factors introduced into clinical trials, this report summarizes current issues of autoantibodies to primary regulators for terminal hematopoiesis.
Export Options
About this article
Cite this article as:
Kato Takashi and Miyazaki Hiroshi, Therapeutically-induced Autoantibodies in Patients Treated with Recombinant Hematopoietic Growth Factors: A Brief Summary, Current Pharmaceutical Design 2003; 9 (14) . https://dx.doi.org/10.2174/1381612033455044
DOI https://dx.doi.org/10.2174/1381612033455044 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antibodies for Therapeutic Uses and the Evolution of Biotechniques
Current Medicinal Chemistry Probiotics and Oral Health
Current Pharmaceutical Design SCYL1-BP1 Affects Cell Cycle Arrest in Human Hepatocellular Carcinoma Cells via Cyclin F and RRM2
Anti-Cancer Agents in Medicinal Chemistry Design, Synthesis and Biological Evaluation of 3-(3,4,5-Trimethoxyphenyl)- 5-(2-(5-arylbenzo[b]thiophen-3-yl)oxazol-5-yl)isoxazole Derivatives as Anticancer Agents
Letters in Organic Chemistry Histamine and Histaminergic Receptors in Colorectal Cancer: From Basic Science to Evidence-based Medicine
Anti-Cancer Agents in Medicinal Chemistry Chemical Variability and Antioxidant Activities of the Essential Oils of the Aerial Parts of Ammoides verticillata and the Roots of Carthamus caeruleus and their Synergistic Effect in Combination
Combinatorial Chemistry & High Throughput Screening Screening and Partial Purification of Cholinesterase Inhibitor from Microalgae
Current Enzyme Inhibition Medicinal Properties of the Jamaican Pepper Plant Pimenta dioica and Allspice
Current Drug Targets A Review of the Recent Developments in Synthetic Anti-Breast Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Targeting Hypoxia for Sensitization of Tumors to Radio- and Chemotherapy
Current Cancer Drug Targets n-3 Polyunsaturated Fatty Acids and the Prevention of Colorectal Cancer: Molecular Mechanisms Involved
Current Medicinal Chemistry Molecular Characteristics of Autoimmune Pancreatitis
Current Pharmaceutical Design The Calcium-Sensing Receptor as a Regulator of Cellular Fate in Normal and Pathological Conditions
Current Molecular Medicine Applications of Natural Polymeric Materials in Solid Oral Modified-Release Dosage Forms
Current Pharmaceutical Design Breast Cancer in the Personal Genomics Era
Current Genomics Thyroid Hormone Levels in the Prefrontal Cortex of Post-Mortem Brains of Alzheimers Disease Patients
Current Aging Science Virtual Screening of NCI Diversity Set II Lead to New Cyclin-Dependent Kinases 5 Inhibitors Using AutoDock
Letters in Drug Design & Discovery Optimization of Drug Safety Profile in Inflammatory Bowel Disease Through a Personalized Approach
Current Drug Targets The Role of EGFR-Met Interactions in the Pathogenesis of Glioblastoma and Resistance to Treatment
Current Cancer Drug Targets Chronobiology of the Neuroimmunoendocrine System and Aging
Current Pharmaceutical Design